One of those genes, K -
Ras, which was discovered nearly 30 years ago, is mutated in 30 percent of human
tumors, including 90 percent of pancreatic cancers, 40 percent of colon cancers, and 20 percent of non-small cell
lung cancers.
This demonstrated that non-small-cell
lung cancer selectively requires autophagy for
tumor development and that therapeutically targeting autophagy may be an alternative to targeting
Ras.
Mutations in one of these genes, NF1 — a known
tumor suppressor gene that regulates the RTK /
RAS / RAF pathway — had previously been reported in
lung cancer.
22) Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly - Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, DePinho
RA, Kemp CJ, Varmus HE, Hanash SM (2011)
Lung cancer signatures in plasma based on proteome profiling of mouse
tumor models.